Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

References

• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiGOral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelinesChest20121412 Supple44Se88S22315269
   PubMed Web of Science ®Google Scholar
• FanolaCLCurrent and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatranVasc Health Risk Manag20151127128226064057
   PubMedGoogle Scholar
• MentJDirect oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillationVasc Health Risk Manag20151131733226089678
   PubMedGoogle Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• FujiTFujitaSKawaiYEfficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-VThromb J2015132726269694
   PubMed Web of Science ®Google Scholar
• FujiTWangCJFujitaSSafety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trialThromb Res201413461198120425294589
   PubMed Web of Science ®Google Scholar
• NICEEdoxaban for Treating and Preventing Deep Vein Thrombosis and Pulmonary EmbolismLondonNational Institute for Health and Care Excellence Available from: https://www.nice.org.uk/guidance/ta354Accessed 2015
   Google Scholar
• Lixiana Edoxaban Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002629/human_med_001874.jsp&mid=WC0b01ac058001d124Accessed October 24, 2015
   Google Scholar
• ChanNCBhagirathVEikelboomJWProfile of betrixaban and its potential in the prevention and treatment of venous thromboembolismVasc Health Risk Manag20151134335126170684
   PubMed Web of Science ®Google Scholar
• BlannANonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come inVasc Health Risk Manag20151148949226316773
   PubMedGoogle Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
   PubMed Web of Science ®Google Scholar
• Chai-AdisaksophaCCrowtherMIsayamaTLimWThe impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysisBlood2014124152450245825150296
   PubMed Web of Science ®Google Scholar
• KakkosSKKirkilesisGITsolakisIAEditor’s choice – efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trialsEur J Vasc Endovasc Surg201448556557524951377
   PubMed Web of Science ®Google Scholar
• WeitzJIPollackCVJrPractical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulantsThromb Haemost20151145 Epub 2015 Jul 9
   Google Scholar
• CrowtherMCrowtherMAAntidotes for novel oral anticoagulants: current status and future potentialArterioscler Thromb Vasc Biol2015351736174526088576
   PubMed Web of Science ®Google Scholar
• EbrightJMousaSAOral anticoagulants and status of antidotes for the reversal of bleeding riskClin Appl Thromb Hemost201521210511425115762
   PubMed Web of Science ®Google Scholar
• WysokinskiWEMcBaneRDiiPeriprocedural bridging management of anticoagulationCirculation2012126448649022825410
   PubMed Web of Science ®Google Scholar
• LiottaEMLevasseur-FranklinKENaidechAMReversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixabanCurr Opin Crit Care201521212713325689124
   PubMed Web of Science ®Google Scholar
• PaikinJSHirshJChanNCGinsbergJSWeitzJIEikelboomJWTiming the first post-operative dose of anticoagulants: lessons learned from clinical trialsChest201514858759525927951
   PubMed Web of Science ®Google Scholar
• SchulmanSCarrierMLeeAYPerioperative management of dabigatran: a prospective cohort studyCirculation2015132316717325966905
   PubMed Web of Science ®Google Scholar
• PollackCVJrCoagulation assessment with the new generation of oral anticoagulantsEmerg Med J Epub 2015 May 18
   Web of Science ®Google Scholar
• WangXMondalSWangJEffect of activated charcoal on apixaban pharmacokinetics in healthy subjectsAm J Cardiovasc Drugs201414214715424277644
   PubMed Web of Science ®Google Scholar
• van RynJSiegerPKink-EibandMGansserDClemensAAdsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitroBlood200911422440440
   Web of Science ®Google Scholar
• Chai-AdisaksophaCHillisCLimWBoonyawatKMoffatKCrowtherMHemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic reviewJ Thromb Haemost2015131790179826270886
   PubMed Web of Science ®Google Scholar
• SarodeRMillingTJJrRefaaiMAEfficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb studyCirculation2013128111234124323935011
   PubMed Web of Science ®Google Scholar
• PabingerIBrennerBKalinaUKnaubSNagyAOstermannHProthrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trialJ Thromb Haemost20086462263118208533
   PubMed Web of Science ®Google Scholar
• ZahirHBrownKSVandellAGEdoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrateCirculation20151311829025403645
   PubMed Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation2011124141573157921900088
   PubMed Web of Science ®Google Scholar
• LeviMMooreKTCastillejosCFComparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteersJ Thromb Haemost20141291428143624811969
   PubMed Web of Science ®Google Scholar
• MarluRHodajEParisAAlbaladejoPCracowskiJLPernodGEffect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteersThromb Haemost2012108221722422627883
   PubMed Web of Science ®Google Scholar
• Idarucizumab Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm467396.htmAccessed: November 2, 2015
   Google Scholar
• Boehringer Ingelheim’s Investigational Antidote for Pradaxa^® (dabigatran etexilate mesylate) receives FDA breakthrough therapy designation Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/4-23-2015-fda-grants-priority-review-boehringer-ingelheims-biologics-license-application-idarucizumab.htmlAccessed October 10, 2015
   Google Scholar
• Portola pharmaceuticals receives breakthrough therapy designation from FDA for andexanet alfa (PRT4445*), investigational factor Xa inhibitor antidote Available from: http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=1879666Accessed August 5, 2015
   Google Scholar
• LaulichtBBakhruSLeeCSmall molecule antidote for anticoagulantsCirculation2012126A11395
   Web of Science ®Google Scholar
• AnsellJEBakhruSHLaulichtBEUse of PER977 to reverse the anticoagulant effect of edoxabanN Engl J Med2014371222141214225371966
   PubMed Web of Science ®Google Scholar
• Perosphere and daiichi sankyo enter into a clinical trial collaboration agreement for phase 3 studies of PER977 to investigate reversal of the anticoagulant activity of the investigational factor Xa-inhibitor edoxaban Available from: http://perosphere.com/content/media/documents/PerosphereandDaiichiSankyoEnterintoaClinicalTrialAgreementforPhase3.pdfAccessed October 10, 2015
   Google Scholar
• LuGKothaJCardenasJMIn vitro characterization of andexanet alfa (PRT064445), a specific fXa inhibitor antidote versus aripazine (PER977), a non-specific reversal agentCirculation2014130A18218
   Web of Science ®Google Scholar
• LuGDeGuzmanFRHollenbachSJA specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNat Med201319444645123455714
   PubMed Web of Science ®Google Scholar
• CrowtherMVandanaMMichaelKA phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for fxa inhibitors (abstract)Blood2013122213636
   Web of Science ®Google Scholar
• CrowtherMLevyGLuGANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitorsCirculation201413021052126
   Google Scholar
• CrowtherMGoldALuGANNEXA (TM)-A PART 2: a phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet ALFA (PRT064445), a universal antidote for factor XA (FXA) inhibitorsJ Thromb Haemost2015138485
   Web of Science ®Google Scholar
• LuGLinJCoffeyGCurnutteJTConleyPBInteraction of andexanet alfa, a universal antidote to fXA inhibitors, with tissue factor pathway inhibitor enhances reversal of fXA inhibitor-induced anticoagulationJ Thromb Haemost201513634635
   Web of Science ®Google Scholar
• SchieleFvan RynJCanadaKA specific antidote for dabigatran: functional and structural characterizationBlood2013121183554356223476049
   PubMed Web of Science ®Google Scholar
• GlundSStangierJSchmohlMSafety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialLancet201538668069026088268
   PubMed Web of Science ®Google Scholar
• GlundSMoschettiVNorrisSA randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThromb Haemost2015113594395125789661
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med201537351152026095746
   PubMed Web of Science ®Google Scholar
• LaulichtBBakhruSSteinerSPER977 (ciraparantag) reverses edoxaban anticoagulation at steady state and has no effect on reanticoagulation at the next scheduled doseEur Heart J201536 Abstract Supplement
   Web of Science ®Google Scholar